{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "ALKS",
  "name": "Alkermes plc",
  "url": "https://orbyd.app/dossiers/ALKS/",
  "json_url": "https://orbyd.app/dossiers/ALKS.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Orexin (OX2R) re-rate has moved from discovery to consensus: 2026-07-13 long-term extension data confirmed durable wakefulness and Needham lifted PT to $62, but JPMorgan reinstated Neutral at $60 as spot presses the $56–62 target band. Sell-side has caught up; the tape is extended and catalyst-light into the ~early-August Q2 print, favoring a pullback to the $42 shelf over a chase. Next true binary is the Q4 idiopathic-hypersomnia readout.",
  "invalidation_trigger": "A weekly close below $42 loses the pre-SLEEP breakout shelf and rising 20-EMA and breaks the orexin re-rate base; secondarily, an OX2R Phase 3 hepatotoxicity signal (class read-through from Takeda's halted TAK-994) or a CRL/slip on Takeda's Q3 oveporexton PDUFA removes the de-risking pillar.",
  "catalyst_date": "2026-08-06",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "precision-biotech-therapeutics",
    "cyclical-industrials"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Vibrance-2 NT2 topline already public and positive; SLEEP 2026 (2026-06-17, Richard Bogan oral) is detailed/secondary data.",
    "Next true binary is the alixorexton idiopathic-hypersomnia Phase 2 readout expected Q4 2026.",
    "Competitor watch: Takeda oveporexton PDUFA Q3 2026, possible 2H 2026 launch — first orexin to market in NT1.",
    "Class liver-safety overhang: Takeda's earlier TAK-994 halted for hepatotoxicity; any OX2R Phase 3 liver signal hits the whole theme.",
    "Balance-sheet note: Avadel deal added $1.525B term loans due 2031 (~$775M cash deployed); deleveraging depends on the commercial base.",
    "Q1 2026: revenue $392.9M (+28.2% YoY) beat $359M consensus; FY2026 guide $1.73-1.84B. Q2 print expected early August (outside catalyst window).",
    "Listed orexin pure-play peer for correlation: Centessa (ORX750/ORX142). LUMRYZ competes with Jazz Xywav/Xyrem.",
    "SLEEP 2026 (2026-06-17) sell-the-news did NOT materialize — Vibrance-2 met dual primary endpoints; PTs raised post-print to $61 (Needham 06-24), $50 (TD Cowen 06-22), $54 (Needham 06-18).",
    "Next true binary: alixorexton idiopathic-hypersomnia Phase 2 readout, Q4 2026.",
    "Q2 2026 print expected ~early August — outside any 30-day catalyst window; revenue/guide check vs FY $1.73-1.84B, not a binary.",
    "Competitor/validator: Takeda oveporexton PDUFA Q3 2026, possible NT1 launch 2H 2026 — first orexin to market.",
    "Class liver-safety overhang: Takeda's earlier TAK-994 halted for hepatotoxicity; any OX2R Phase 3 liver signal is a theme-wide risk.",
    "Avadel deal added $1.525B term loans due 2031 (~$775M cash deployed); deleveraging leans on the commercial base.",
    "Correlation peers: Centessa (ORX750/ORX142) for class sentiment; LUMRYZ competes with Jazz Xywav/Xyrem.",
    "Q2 2026 print expected ~early August (historically late-July/early-Aug) — revenue/guide check vs FY $1.73-1.84B; thesis is NOT earnings-driven, so this is a fundamentals read, not a binary.",
    "Next true binary: alixorexton idiopathic-hypersomnia Phase 2 readout, Q4 2026 (outside 30-day window).",
    "Class liver-safety overhang: Takeda TAK-994 halted for hepatotoxicity; any OX2R Phase 3 liver signal is theme-wide, not name-specific.",
    "Avadel/LUMRYZ deal added $1.525B term loans due 2031 (~$775M cash deployed); deleveraging leans on the commercial base's growth rate.",
    "Sell-side has caught up (Needham $62 07-13, JPM Neutral $60 07-13, TD Cowen $50, RBC $56) — theme now MATURING/widely-owned, not early; fresh entries favor a pullback to the $40-42 shelf over a chase into the target band.",
    "2026-07-08: VIVITROL authorized-generic supply agreement with Amneal terminated without penalties — minor positive for the legacy commercial base."
  ],
  "body_markdown": "## Current Thesis\nThe trade remains the re-rate of a profitable legacy CNS franchise into an orexin-2 receptor (OX2R) sleep-medicine leader — but the narrative has moved from discovery to consensus. Alkermes spent a decade as an injectables and addiction house (VIVITROL, ARISTADA, LYBALVI); the market now prices alixorexton (ALKS 2680) as the value driver. The 2026-06-17 Vibrance-2 print (narcolepsy type 2, dual primary endpoints met) drew no sell-the-news, and on 2026-07-13 an interim analysis of the long-term extension study confirmed sustained, clinically meaningful wakefulness gains — closing off the durability question that shadows any novel mechanism. The sell-side has now caught up: Needham lifted its target to $62 (2026-07-13) while JPMorgan reinstated coverage at Neutral with a $60 target the same day. With spot pressing the $56–$62 target cluster and no dated binary until the Q4 idiopathic-hypersomnia readout, the setup has shifted from an early accelerating re-rate to a maturing, extended tape where fresh entries pay full price.\n\n## Bull Case\n- 2026-07-13: interim long-term extension analysis showed alixorexton sustained clinically meaningful wakefulness improvement in narcolepsy — durability, the main open question on a new mechanism, now supported by real data rather than a single acute readout.\n- 2026-06-17: Vibrance-2 (NT2, n=93) met dual primary endpoints — the first large positive OX2R Phase 2 in narcolepsy type 2, a segment where Takeda is NT1-first.\n- Vibrance-1 (NT1, n=92) hit its Maintenance of Wakefulness Test primary with dose-dependent gains; FDA granted Breakthrough Therapy for NT1.\n- Class de-risked externally: Takeda's oveporexton met every Phase 3 endpoint, NDA accepted 2026-02-10 under priority review, PDUFA Q3 2026 — the mechanism works in humans.\n- Analyst cluster keeps ratcheting: Needham $62 (07-13), $61 (06-24), TD Cowen $50 (06-22), RBC Outperform $56 (06-09) — targets rising after known prints is the signature of a live theme.\n- Commercial base funds the pipeline: Q1 2026 revenue $392.9M (+28.2% YoY) beat the $359M consensus; FY2026 guide $1.73–1.84B; LUMRYZ FY guide $350–370M.\n- 2026-07-08: VIVITROL authorized-generic supply agreement with Amneal terminated without penalties — removes a scheduled generic drag on a franchise that still funds R&D.\n\n## Bear Case\n- Sell-side has arrived: JPMorgan reinstated at Neutral / $60 (2026-07-13), signaling the easy re-rate gap has closed with spot inside the $56–$62 target band.\n- Extended structure: the name has run roughly 75%+ off the $25.17 52-week low and pushed through the $45.76 prior high, with RSI parked in the 80s through June — a stretched tape prone to mean reversion on any wobble.\n- Catalyst vacuum: the SLEEP print and long-term data are spent; the next true binary — alixorexton idiopathic-hypersomnia Phase 2 — is not until Q4 2026, with only the early-August Q2 revenue print in between.\n- Competitive clock: Takeda is 2–3 years ahead and likely first orexin to market in NT1, with a possible 2H 2026 launch.\n- Class liver overhang: Takeda's earlier TAK-994 was halted for hepatotoxicity; any OX2R Phase 3 liver signal hits the whole theme, not just this name.\n- Balance sheet: the Avadel/LUMRYZ deal added $1.525B of term loans due 2031 (~$775M cash deployed); deleveraging leans on the commercial base holding its growth rate.\n\n## Setup & Price Structure\nOff a $25.17 52-week low, the stock cleared its $45.76 prior high after the 2026-06-17 print and traded into price discovery, and the subsequent target raises to $62 (Needham) validated the push rather than fading it. That is also the problem for a fresh buyer: the published band now runs from roughly $50 (TD Cowen) to $62 (Needham), JPMorgan pegs fair value at $60 with a Neutral rating, and spot sits inside that band rather than below it — the mispricing the sell-side ignored in May has been arbitraged out. Structural support is the pre-SLEEP breakout shelf at $40–$42 and the rising 20-EMA beneath it; that shelf is the line between orderly consolidation of a won re-rate and a leg that is over. For a name with no dated binary inside 30 days, the higher-probability entry is a pullback that resets the extension into the $40–$42 zone, not a chase into the target cluster. Buying the parabolic extension once a theme has flipped from early to widely-owned is where momentum books give back the move.\n\n## Catalyst Calendar (next 30 days)\n- ~2026-08-06 (est.): Q2 2026 earnings print — revenue and FY-guide check against $1.73–1.84B and LUMRYZ $350–370M; a fundamentals read, not a binary for the orexin thesis. Historically reports late-July/early-August, so watch for a date confirmation.\n- Q3 2026 (FDA date TBD): Takeda oveporexton PDUFA — external class validator; an approval cements OX2R commercially, a CRL/slip is a theme-wide negative read-through.\n- No dated alixorexton binary inside 30 days; the next true readout (idiopathic-hypersomnia Phase 2) is Q4 2026, outside this window.\n\n## What Would Change Our Mind\nThe bullish read weakens if the early-August Q2 print shows the commercial base decelerating below the FY $1.73–1.84B guide — the base is what funds the pipeline and services the 2031 term loans — or if LUMRYZ tracks below its $350–370M guide. A weekly close below $42 would say the re-rate base has failed and the momentum leg is done, at which point standing aside beats holding a broken structure into a catalyst-light stretch. On the class, an OX2R hepatotoxicity signal in any Phase 3 program (read-through from Takeda's halted TAK-994) or a CRL/delay on the Q3 oveporexton PDUFA would pull the de-risking pillar out from under the entire orexin complex. Conversely, a clean Q2, an oveporexton approval, and a hold above $42 would re-arm the setup for the Q4 idiopathic-hypersomnia readout and justify pressing on a pullback.\n\n## Correlation Notes\nOrexin pure-play sentiment reads off Centessa (ORX750/ORX142) and, upstream, Takeda's oveporexton newsflow — a class hepatotoxicity headline moves all three together regardless of company-specific data. On the commercial side, LUMRYZ competes directly with Jazz Pharmaceuticals' Xywav/Xyrem in oxybate, so Jazz oxybate share commentary is a read on the acquired franchise. VIVITROL/ARISTADA/LYBALVI tie the name to broader CNS/psychiatry demand, but those are the legacy base the market is looking through. Beta to the biotech tape (XBI/IBB) is the ambient risk: in a biotech risk-off, an extended, widely-owned re-rate like this one gives back faster than the group.",
  "first_seen": "2026-06-10",
  "last_analyzed": "2026-07-18T08:35:46+00:00",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}